Naphthalimide Derivatives for Leishmaniasis Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for bacterial, viral, and neoplastic diseases often require medical supervision, cause severe side effects, and have dose-restricting toxicity issues, limiting their effectiveness and solubility, necessitating the development of novel active agents that are highly bioavailable.
Innovation Solution
Development of bisnaphthalimidopropyl-derived molecules with specific chemical structures (Formulas I to VIII) that are designed to be effective against bacterial, viral, and neoplastic diseases, with optimized solubility and bioavailability, and synthesized through a method involving reactions with paramethyl sulphonyl chloride and diamino compounds.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If naphthalimide compounds are used to treat diseases, then therapeutic effectiveness is improved, but dose-restricting toxicity and central nervous system toxicity occur
Solution Approach 1:
The patent modifies the chemical structure of naphthalimide compounds by introducing various substituents (R1-R12) and spacer groups with different lengths (n=0-12), thereby changing physical and chemical parameters such as solubility, bioavailability, and metabolic stability. These parameter changes allow the compounds to maintain therapeutic effectiveness while reducing dose-restricting toxicity and central nervous system toxicity through optimized pharmacokinetic properties
Solution Approach 2:
The invention creates composite molecular structures by combining naphthalimide units with various spacer groups (alkane, alkene, alkyne, amine, alcohol, cyanide, sulphonamide, etc.) and substituent groups. This composite approach allows the molecule to integrate multiple functional properties, achieving both high therapeutic effectiveness and reduced toxicity through balanced molecular design
2Reliability
If conventional drugs are administered, then disease treatment is achieved, but severe side effects and dose-restricting toxicity problems occur
Solution Approach 1:
The patent introduces specific functional groups and substituents at particular positions (R1-R12) of the naphthalimide core structure to locally modify molecular properties. This local quality adjustment allows the compound to selectively interact with disease targets while minimizing off-target effects, thereby reducing severe side effects while maintaining treatment effectiveness
Solution Approach 2:
The spacer groups acting as intermediaries between naphthalimide units modify the molecular behavior and interaction patterns. These intermediary structures (with varying lengths and compositions) mediate the balance between therapeutic activity and side effect profile, allowing effective disease treatment with reduced severe side effects
3Reliability
If known naphthalimide molecules are used, then therapeutic activity is achieved, but solubility and bioavailability are limited
Solution Approach 1:
The patent systematically varies chemical parameters including spacer length (n=0-12), substituent types (hydrophilic and hydrophobic groups), and molecular weight to optimize the balance between therapeutic activity, solubility, and bioavailability. These parameter changes enable the compounds to achieve high therapeutic activity while maintaining excellent solubility and bioavailability characteristics
Solution Approach 2:
The invention creates multiple analogues and derivatives of the core naphthalimide structure with systematic variations in spacer and substituent groups. This copying approach with incremental modifications allows identification of optimal structures that combine high therapeutic activity with improved solubility and bioavailability
Data Source
Figure 1
AI summary
The present patent application discloses naphthalimide derivatives and in particular e.g. N-aryl-substituted naphthalimidopropylamine derivatives (i.e. 2-[3-(amino)propyl]-1H-benz[de]isoquinoline-1,3(2H)- dione derivatives) such as e.g. such as e.g.(Formula I) or (Formula III) as anti-parasitic agents for the treatment of Leishmaniasis. The compounds could also be useful to treat viral, bacterial and/or neoplastic diseases. The description discloses exemplary synthesis as well as biological tests against Leishmania Infantum parasites (e.g. pages 54 to 58; examples 1 to 7). Exemplary compounds are:(example 3)(example 4) 2-(3-((5-amino naphtha lene-l-yl)amino)propyl)-lH-benzo[de]isoq uinoline-1, 3(2 H)-dione (example 5) 2-(3-((5-amino naphtha lene-l-yl)amino)propyl)-lH-benzo[de]isoq uinoline-1, 3(2 H)-dione (example 6)